Literature DB >> 6114851

Current antidepressant drugs: their clinical use.

L E Hollister.   

Abstract

Depression is not only a common disorder, but also one that is readily treatable. Antidepressant drugs play a major role in treatment, although concurrent use of electroconvulsive therapy or psychotherapy may be indicated for some patients. Antidepressant drugs have been most specifically beneficial for patients with 'endogenous' depressions, but they should be used whenever this type of depression cannot be definitely ruled out. Besides the older tricyclic antidepressants and monoamine oxidase inhibitors, a new 'second generation' group of drugs is now available. Although these drugs offer no great therapeutic advantages over the older ones, they may prove to have a more acceptable profile of side effects, may act more quickly, and may show less cardiotoxicity with overdoses. Whether one can classify depression pathogenetically according to various biological markers, such as urinary excretion of the norepinephrine metabolite, 3-methoxy-4-hydroxy phenylglycol, is still uncertain. At present, the choice of antidepressant drug for an individual patient is largely empirical. Besides being useful for treating depression, antidepressants may be used for treating enuresis, chronically painful states, obsessive-compulsive-phobic states, acute panic attacks and cataplectic attacks in narcoleptics. Many studies have tried to define a therapeutic range of plasma concentrations of these drugs, so as to afford a better basis for dosing, but routine monitoring of drug plasma concentrations is seldom needed; the primary indication for doing so would be in the patient who has received what should be an adequate dose but who is still unresponsive. The value of maintenance treatment with antidepressants has been clearly established; the pattern it takes is best determined by the natural history of the disorder in individual patients. Most drug interactions with antidepressants are pharmacodynamic in nature and can be managed by adjusting doses. Pharmacokinetic interactions with various sympatholytic antihypertensive drugs, such as guanethidine, methyldopa and clonidine, are rare but may be serious. Patients with depression may be spared a considerable amount of discomfort, morbidity, and possibly mortality, by judicious use of antidepressant drugs and the other treatments currently available.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6114851     DOI: 10.2165/00003495-198122020-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  88 in total

1.  Experimental and clinical evidence of the antidepressant effect of a beta-adrenergic stimulant.

Authors:  P Simon; Y Lecrubier; R Jouvent; A J Puech; J F Allilaire; D Widlöcher
Journal:  Psychol Med       Date:  1978-05       Impact factor: 7.723

2.  Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline.

Authors:  S Vandel; B Vandel; M Sandoz; G Allers; P Bechtel; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

Review 3.  Antidepressant drugs.

Authors:  B Bopp; J H Biel
Journal:  Life Sci       Date:  1974-02-01       Impact factor: 5.037

4.  Cardiotoxicity of amitriptyline.

Authors:  D C Moir; W B Cornwell; I Dingwall-Fordyce; J Crooks; K O'Malley; M J Turnbull; R D Weir
Journal:  Lancet       Date:  1972-09-16       Impact factor: 79.321

5.  The efficacy of antidepressant drugs. A review of research (1958-1972).

Authors:  J B Morris; A T Beck
Journal:  Arch Gen Psychiatry       Date:  1974-05

6.  The syndrome of inappropriate secretion of antidiuretic hormone associated with amitriptyline administration.

Authors:  M H Luzecky; K D Burman; E R Schultz
Journal:  South Med J       Date:  1974-04       Impact factor: 0.954

7.  Galactorrhea in a patient treated with amoxapine.

Authors:  K Jaffe; S Zisook
Journal:  J Clin Psychiatry       Date:  1978-11       Impact factor: 4.384

8.  Plasma levels of tricyclic antidepressants and clinical efficacy: review of the literature -- part II.

Authors:  S C Risch; L Y Huey; D S Janowsky
Journal:  J Clin Psychiatry       Date:  1979-02       Impact factor: 4.384

9.  Clomipramine: plasma levels, side effects and outcome in obsessive-compulsive neurosis.

Authors:  R S Stern; I M Marks; J Wright; D K Luscombe
Journal:  Postgrad Med J       Date:  1980       Impact factor: 2.401

10.  Excretion of MHPG in normal subjects: implications for biological classification of affective disorders.

Authors:  L E Hollister; K L Davis; J E Overall; T Anderson
Journal:  Arch Gen Psychiatry       Date:  1978-12
View more
  4 in total

1.  Antidepressants.

Authors:  B R Ballinger; J Feely
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-11

Review 2.  The risk-benefit assessment of antidepressant drugs.

Authors:  J A Henry; A J Martin
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Nov-Dec

Review 3.  Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression.

Authors:  G W Dawson; S G Jue; R N Brogden
Journal:  Drugs       Date:  1984-02       Impact factor: 9.546

4.  First-pass metabolism of nomifensine in dogs.

Authors:  R Lindberg; R Sellman; E Iisalo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jan-Mar       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.